UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Cns Pharmaceuticals Inc (CNSP)

Cns Pharmaceuticals Inc (CNSP)
0.0742 -0.0096 (-11.46%) 16:17 ET [NASDAQ]
0.0740 x 200 0.0960 x 4000
Realtime by (Cboe BZX)
0.0740 x 200 0.0960 x 4000
Realtime 0.0740 -0.0010 (-) 16:17 ET
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.0660
Day High
0.0863
Open 0.0863
Previous Close 0.0838 0.0838
Volume 35,282,541 35,282,541
Avg Vol 45,927,453 45,927,453
Stochastic %K 21.95% 21.95%
Weighted Alpha -92.53 -92.53
5-Day Change -0.0288 (-27.75%) -0.0288 (-27.75%)
52-Week Range 0.0660 - 23.9000 0.0660 - 23.9000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,817
  • Shares Outstanding, K 57,487
  • Annual Sales, $ 0 K
  • Annual Income, $ -18,850 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 2.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -74.97
  • Most Recent Earnings $-0.25 on 11/14/24
  • Next Earnings Date 04/07/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0660 +13.64%
on 02/20/25
Period Open: 0.1019
0.1900 -60.53%
on 02/14/25
-0.0269 (-26.40%)
since 01/17/25
3-Month
0.0660 +13.64%
on 02/20/25
Period Open: 0.1236
0.1900 -60.53%
on 02/14/25
-0.0486 (-39.32%)
since 11/20/24
52-Week
0.0660 +13.64%
on 02/20/25
Period Open: 14.5000
23.9000 -99.69%
on 03/11/24
-14.4250 (-99.48%)
since 02/20/24

Most Recent Stories

More News
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Webcast presentation Wednesday, February 26th at 3:20 PM CET

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here

CNSP : 0.0750 (-10.50%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.0550 (-0.47%)
AREC : 0.5743 (-2.25%)
OTLK : 1.6400 (-3.24%)
AMIX : 2.93 (+2.09%)
CNSP : 0.0750 (-10.50%)
PALI : 0.9800 (+0.37%)
NVNO : 3.82 (+6.41%)
HURA : 3.30 (+3.77%)
GRI : 0.4352 (-17.90%)
CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

HOUSTON, TX / ACCESS Newswire / February 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at BIO CEO & Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, will participate in the BIO CEO & Investor Conference in New...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

In-person presentation today, February 10th at 1:15 PM ET

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Live webcast discussion featuring internationally renowned Glioblastoma Multiforme (GBM) Key Opinion Leaders

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Progress in Pivotal Study of Berubicin for Glioblastoma

CNS Pharmaceuticals (NASDAQ: CNSP) announced updated results from its ongoing pivotal trial evaluating Berubicin, a novel anthracycline crossing the blood-brain barrier, against Lomustine in recurrent...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) to Present Berubicin Trial Update at Society for Neuro-Oncology Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) announced that its abstract on the pivotal trial of Berubicin, a novel treatment for glioblastoma multiforme (“GBM”), has been selected for poster presentation at...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect Event

CNS Pharmaceuticals (NASDAQ: CNSP), focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in a Virtual Investor KOL Connect segment featuring Professor...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into securities...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) Management Participates in Virtual Investor KOL Connect Segment

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals (NASDAQ: CNSP) Announces Participation at Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced...

CNSP : 0.0750 (-10.50%)
CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Webcast presentation on Wednesday, September 25th at 1:55 PM CEST

CNSP : 0.0750 (-10.50%)

Business Summary

CNS Pharmaceuticals Inc. is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors. The company's lead drug includes Berubicin, for the treatment of Glioblastoma Multiforme and potentially for other CNS malignancies. CNS Pharmaceuticals Inc. is...

See More

Key Turning Points

3rd Resistance Point 0.1205
2nd Resistance Point 0.1117
1st Resistance Point 0.0978
Last Price 0.0750
1st Support Level 0.0751
2nd Support Level 0.0663
3rd Support Level 0.0524

See More

52-Week High 23.9000
Fibonacci 61.8% 14.7954
Fibonacci 50% 11.9830
Fibonacci 38.2% 9.1706
Last Price 0.0750
52-Week Low 0.0660

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements